TD Cowen Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00

Key Points

• TD Cowen cut its price target on Myriad to $6.00 (from $7.00) and kept a "hold" rating, implying roughly a 45.8% upside from current levels.
• Myriad's Q1 results missed estimates — GAAP loss of $0.09 vs. -$0.06 and revenue $200.4M vs. $202.4M — sparking a heavy sell‑off that pushed shares to $4.12 on well‑above‑average volume amid negative margins and ROE.
• Despite the miss, insiders (including the CEO and a director) have recently bought stock and management reiterated FY‑2026 revenue guidance of $860M–$880M, citing volume growth in higher‑margin Cancer Care Continuum and Mental Health segments.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) had its price objective lowered by analysts at TD Cowen from $7.00 to $6.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a "hold" rating on the stock. TD Cowen's target price indicates a potential upside of 45.81% from the stock's current price.

Several other equities analysts also recently commented on MYGN. Weiss Ratings restated a "sell (d-)" rating on shares of Myriad Genetics in a research report on Friday, March 27th. UBS Group cut their target price on Myriad Genetics from $8.00 to $6.00 and set a "neutral" rating for the company in a research report on Tuesday, February 24th. Zacks Research upgraded Myriad Genetics from a "strong sell" rating to a "hold" rating in a research report on Thursday, February 26th. Finally, Wells Fargo & Company cut their target price on Myriad Genetics from $6.00 to $5.50 and set an "equal weight" rating for the company in a research report on Wednesday. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $8.50.

Myriad Genetics Price Performance

NASDAQ MYGN traded down $0.92 on Wednesday, reaching $4.12. The company's stock had a trading volume of 6,707,510 shares, compared to its average volume of 1,572,915. The firm has a market cap of $388.62 million, a PE ratio of -1.04 and a beta of 1.81. The business has a 50-day moving average price of $4.78 and a 200 day moving average price of $5.90. Myriad Genetics has a 52 week low of $3.75 and a 52 week high of $8.59. The company has a current ratio of 2.49, a quick ratio of 2.26 and a debt-to-equity ratio of 0.33.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). The business had revenue of $200.40 million for the quarter, compared to the consensus estimate of $202.42 million. Myriad Genetics had a negative return on equity of 6.35% and a negative net margin of 44.38%.The firm's revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.03) EPS. Sell-side analysts expect that Myriad Genetics will post -0.37 EPS for the current year.

Insider Activity at Myriad Genetics

In other Myriad Genetics news, CEO Samraat S. Raha purchased 40,000 shares of the company's stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average cost of $5.00 per share, with a total value of $200,000.00. Following the acquisition, the chief executive officer directly owned 493,104 shares of the company's stock, valued at approximately $2,465,520. This trade represents a 8.83% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director S. Louise Phanstiel purchased 50,407 shares of the company's stock in a transaction that occurred on Thursday, February 26th. The shares were acquired at an average cost of $4.80 per share, with a total value of $241,953.60. Following the completion of the acquisition, the director directly owned 233,951 shares in the company, valued at approximately $1,122,964.80. This represents a 27.46% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 144,507 shares of company stock valued at $694,548 in the last 90 days. 1.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Myriad Genetics

Hedge funds and other institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC increased its holdings in Myriad Genetics by 2,333.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company's stock valued at $25,000 after purchasing an additional 4,480 shares in the last quarter. Quarry LP increased its holdings in Myriad Genetics by 155.6% during the 4th quarter. Quarry LP now owns 4,365 shares of the company's stock valued at $27,000 after purchasing an additional 2,657 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in Myriad Genetics by 1,088.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 4,089 shares of the company's stock valued at $30,000 after purchasing an additional 3,745 shares in the last quarter. Royal Bank of Canada increased its holdings in Myriad Genetics by 129.6% during the 4th quarter. Royal Bank of Canada now owns 4,993 shares of the company's stock valued at $31,000 after purchasing an additional 2,818 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Myriad Genetics during the 2nd quarter valued at $37,000. 99.02% of the stock is owned by institutional investors and hedge funds.

More Myriad Genetics News

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Company reiterated FY‑2026 revenue guidance of $860M–$880M and highlighted year‑over‑year test volume growth in its Cancer Care Continuum (+13%) and Mental Health (+7%) segments, which management cites as evidence of ongoing progress in higher‑margin areas. Press Release
• Neutral Sentiment: Wells Fargo lowered its price target from $6.00 to $5.50 and kept an "equal weight" rating — a modest downgrade but still implies upside from current levels, signaling analysts see limited near‑term catalysts but not a more severe downgrade. Benzinga TickerReport
• Neutral Sentiment: Full Q1 earnings call transcript is available for investors who want management’s tone on demand trends, margin drivers and cadence for the rest of the year. Use the call transcript to judge credibility of guidance and segment outlook. Earnings Call Transcript
• Negative Sentiment: Q1 results missed estimates: GAAP loss of $0.09/sh vs. consensus -$0.06 and revenue $200.4M vs. $202.4M expected. The EPS and revenue shortfalls, plus a negative net margin (~44%) and negative ROE, are the primary drivers of today’s selling pressure. Zacks
• Negative Sentiment: Market writeups describe a heavy sell‑off after the Q1 miss; trading volume is well above average, indicating institutional selling and weaker near‑term sentiment. Seeking Alpha

Myriad Genetics Company Profile

Myriad Genetics NASDAQ: MYGN is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual's risk for various hereditary conditions and to guide personalized treatment decisions. The company's core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women's health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.